{"id":742311,"date":"2013-10-01T06:30:00","date_gmt":"2013-10-01T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/"},"modified":"2023-03-22T00:04:34","modified_gmt":"2023-03-22T04:04:34","slug":"merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/","title":{"rendered":"Merck Announces Global Initiative to Sharpen Commercial and R&#038;D Focus"},"content":{"rendered":"<p class=\"bwalignc\">       Company Redesigns Operating Model; Reduces Cost Base     <\/p>\n<ul>\n<li>         Initiative targets net reduction in annual operating expenses of          approximately $2.5 billion by the end of 2015       <\/li>\n<li>         Plan includes new workforce reductions of approximately 8,500          positions, in addition to pending, previously announced reductions       <\/li>\n<li>         Company reaffirmed 2013 full-year non-GAAP EPS target of $3.45 to          $3.55; revised GAAP EPS range to $1.58 to $1.82       <\/li>\n<\/ul>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced a global initiative to sharpen its commercial and<br \/>\n      research and development (R&amp;D) focus. The multi-year initiative will<br \/>\n      enable Merck to better target its resources behind those opportunities<br \/>\n      that have the potential to deliver the greatest return on investment,<br \/>\n      including bolstering its pipeline and implementing a more agile<br \/>\n      operating model, with a significantly reduced, more flexible cost<br \/>\n      structure.\n    <\/p>\n<p>\n      \u201cThese actions will make Merck a more competitive company, better<br \/>\n      positioned to drive innovation and to more effectively commercialize<br \/>\n      medicines and vaccines for the people who need them,\u201d said Kenneth C.<br \/>\n      Frazier, chairman and chief executive officer, Merck. \u201cToday\u2019s<br \/>\n      announcement further underscores that we are committed to improving our<br \/>\n      performance in the short term while also investing for the long term to<br \/>\n      create value for patients, customers and shareholders.\u201d\n    <\/p>\n<p>\n      The company expects to realize approximately $2.5 billion in annual net<br \/>\n      cost savings by the end of 2015 and estimates that $1.0 billion, or 40<br \/>\n      percent, of the savings will be realized by the end of 2014. The company<br \/>\n      anticipates that the substantial majority of savings will come from<br \/>\n      marketing and administrative expenses and R&amp;D. These savings are off of<br \/>\n      the company\u2019s full-year 2012 expense levels. By the end of 2015, the<br \/>\n      workforce reductions announced today, combined with pending, previously<br \/>\n      announced reductions of approximately 7,500, will result in a decrease<br \/>\n      of about 20 percent in Merck\u2019s total global workforce of 81,000<br \/>\n      employees. Total pre-tax costs for the new restructuring program are<br \/>\n      estimated to range between $2.5 billion and $3.0 billion. The company<br \/>\n      estimates that approximately two-thirds of these costs will result in<br \/>\n      cash outlays, primarily related to separation expense, and approximately<br \/>\n      one-third are non-cash, primarily related to accelerated depreciation of<br \/>\n      facilities to be closed or divested.\n    <\/p>\n<p>\n      \u201cWhile these actions are essential to ensure that Merck can continue to<br \/>\n      fulfill its mission into the future, they are nevertheless difficult<br \/>\n      decisions because they affect our dedicated and talented colleagues. We<br \/>\n      appreciate the contributions of all our employees, and we will support<br \/>\n      them during this time of transformation,\u201d said Frazier.\n    <\/p>\n<p>\n      Overall, this global initiative will focus on three key areas:\n    <\/p>\n<p>\n      <b>Redesigned Operating Model and Reduced Cost Base<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        The company evaluated all aspects of how it operates as a business and<br \/>\n        is adopting a significantly streamlined and more flexible cost<br \/>\n        structure and operating model in response to business challenges and<br \/>\n        the rapidly changing external environment.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Through new cost efficiencies, the company will:<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Better allocate resources across the enterprise to those areas<br \/>\n            that present the highest-potential growth opportunities, such as<br \/>\n            its anti-PD-1 immunotherapy program for oncology;\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Invest in new licensing and business development activities to<br \/>\n            acquire external innovation and commercial opportunities to<br \/>\n            strengthen the pipeline; and\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Maintain a high level of cash returned to shareholders through<br \/>\n            both the dividend and the company\u2019s stock repurchase program.\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        The company will also reduce its global real estate footprint,<br \/>\n        particularly in New Jersey where it is headquartered. It will also<br \/>\n        continue to move forward with ongoing plans to improve the efficiency<br \/>\n        of its manufacturing and supply network.\n      <\/li>\n<\/ul>\n<p>\n      <b>Sharpened Commercial Focus<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Within the core human pharmaceutical and vaccine business, Merck will<br \/>\n        continue to support its in-line portfolio and prepare for promising<br \/>\n        launches in the pipeline.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The company will increase its focus on the key therapeutic areas that<br \/>\n        meet unmet medical needs, provide the best opportunities for the<br \/>\n        business and deliver the greatest value for customers \u2013 diabetes,<br \/>\n        acute hospital care, vaccines and oncology.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Merck is creating a new, integrated unit to ensure that the company is<br \/>\n        prepared to successfully bring MK-3475, its investigational anti-PD-1<br \/>\n        immunotherapy, to patients throughout the world.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Geographically, the company will increase its focus in ten prioritized<br \/>\n        markets, which account for the majority of revenue in its<br \/>\n        pharmaceutical and vaccine business. These markets are the United<br \/>\n        States, Japan, France, Germany, Canada, United Kingdom, China, Brazil,<br \/>\n        Russia and Korea.\n      <\/li>\n<\/ul>\n<p>\n      <b>Refocused and Prioritized Research and Development<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Merck has prioritized its R&amp;D efforts to focus on candidates capable<br \/>\n        of providing unambiguous, promotable advantages to patients and payers.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        This focus will include programs such as the company\u2019s anti-PD-1<br \/>\n        immunotherapy program in oncology, BACE for Alzheimer\u2019s disease<br \/>\n        (MK-8931), its next generation HCV program and V503, the company\u2019s<br \/>\n        9-valent HPV vaccine.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Merck will pursue emerging product opportunities independent of<br \/>\n        therapeutic area or modality and build its biologics capabilities.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The company will out-license or discontinue selected late-stage<br \/>\n        clinical development assets and reduce its focus on platform<br \/>\n        technologies.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The company will make externally sourced programs a greater component<br \/>\n        of its pipeline strategy.\n      <\/li>\n<\/ul>\n<p>\n      <b>Financial Targets<\/b>\n    <\/p>\n<p>\n      Merck reiterated its full-year 2013 non-GAAP<sup>1<\/sup> (generally<br \/>\n      accepted accounting principles) earnings per share (EPS) target range of<br \/>\n      $3.45 to $3.55 and revised its GAAP range to be between $1.58 and $1.82.<br \/>\n      The company expects to record charges relating to the new restructuring<br \/>\n      program of approximately $900 million to $1.1 billion in 2013, a<br \/>\n      majority of which will be recorded in the third quarter. The 2013<br \/>\n      non-GAAP EPS target range excludes acquisition-related costs, costs<br \/>\n      related to restructuring programs and certain other items. A<br \/>\n      reconciliation of anticipated 2013 EPS, as reported in accordance with<br \/>\n      GAAP to non-GAAP EPS that excludes certain items, is provided in the<br \/>\n      table below.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            $ in millions, except EPS amounts\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          <b>Full Year 2013<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          GAAP EPS\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          $1.58 to $1.82\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Difference<sup>2<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          1.87 to 1.73\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Non-GAAP EPS that excludes items listed below\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          $3.45 to $3.55\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Acquisition-related costs<sup>3<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          $5,400 to $5,200\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Restructuring costs\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          1,900 to 1,600\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Net decrease (increase) in income before taxes\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          7,300 to 6,800\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Income tax (benefit) expense<sup>4<\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          (1,700) to (1,600)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignb bwalignl bwsinglebottom\">\n          Decrease (increase) in net income\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          $5,600 to $5,200\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      <b>Analyst Conference Call<\/b>\n    <\/p>\n<p>\n      Investors, journalists and the general public may access a live audio<br \/>\n      webcast of the call today at 8:30 a.m. EDT on Merck\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;esheet=50719858&amp;newsitemid=20131001005957&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Finvestors%2Fevents-and-presentations%2Fhome.html&amp;index=1&amp;md5=32b1595f7820a06928bcb7d74038a5cf\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/investors\/events-and-presentations\/home.html<\/a>.<br \/>\n      Software needed to listen to the webcast is available on Merck\u2019s website<br \/>\n      and should be downloaded prior to the beginning of the webcast. A replay<br \/>\n      of the webcast will be available at approximately 11:00 a.m. EDT on Oct.<br \/>\n      1 and will remain on the website for 12 months.\n    <\/p>\n<p>\n      Institutional investors and analysts can participate in the call by<br \/>\n      dialing (706) 758-9927 or (877) 381-5782 and using ID code number<br \/>\n      72330994.\n    <\/p>\n<p>\n      Members of the media are invited to monitor the call by dialing (706)<br \/>\n      758-9928 or (800) 399-7917 and using ID code number 72330994.<br \/>\n      Journalists who wish to ask questions are requested to contact a member<br \/>\n      of Merck&#8217;s Media Relations team at the conclusion of the call.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50719858&amp;newsitemid=20131001005957&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=b4691d7609ab026123b6041bebf05ed5\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter.com%2FMerck&amp;esheet=50719858&amp;newsitemid=20131001005957&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=edf67b78fddf6dfa40a073125898f4b5\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50719858&amp;newsitemid=20131001005957&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=a31b6422ecef06dfdb84b1874ab926d6\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50719858&amp;newsitemid=20131001005957&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=1c18bb7b13f3eff7b16ade6434fc0e76\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50719858&amp;newsitemid=20131001005957&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=c222918e743f16c667538acdf0b931ef\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> Merck is providing certain non-GAAP information that<br \/>\n      excludes certain items because of the nature of these items and the<br \/>\n      impact they have on the analysis of underlying business performance and<br \/>\n      trends. Management believes that providing this information enhances<br \/>\n      investors\u2019 understanding of the company\u2019s performance. This information<br \/>\n      should be considered in addition to, but not in lieu of, information<br \/>\n      prepared in accordance with GAAP.\n    <\/p>\n<p>\n      <sup>2 <\/sup>Represents the difference between calculated GAAP EPS and<br \/>\n      calculated non-GAAP EPS, which may be different than the amount<br \/>\n      calculated by dividing the impact of the excluded items by the<br \/>\n      weighted-average shares for the period.\n    <\/p>\n<p>\n      <sup>3 <\/sup>Includes expenses for the amortization of intangible assets<br \/>\n      recognized as a result of mergers and acquisitions, as well as<br \/>\n      intangible asset impairment charges. Also includes integration and other<br \/>\n      costs associated with mergers and acquisitions.\n    <\/p>\n<p>\n      <sup>4 <\/sup>Includes the estimated tax impact on the reconciling items,<br \/>\n      as well as a net favorable impact related to the settlements of certain<br \/>\n      federal income tax issues.\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131001005957r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Kelley Dougherty,        908-423-4291<br \/>Steven Cragle, 908-423-3461<br \/>or<br \/>Investor        Contacts:<br \/>Carol Ferguson, 908-423-4465<br \/>Joe Romanelli,        908-423-5185     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company Redesigns Operating Model; Reduces Cost Base Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015 Plan includes new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions Company reaffirmed 2013 full-year non-GAAP EPS target of $3.45 to $3.55; revised GAAP EPS range to $1.58 to $1.82 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a global initiative to sharpen its commercial and research and development (R&amp;D) focus. The multi-year initiative will enable Merck to better target its resources behind those opportunities that have the potential to deliver the greatest return on investment, including bolstering its pipeline and implementing a more agile operating model, with a significantly reduced, more flexible cost structure. \u201cThese actions will make Merck a more competitive company, better positioned to drive innovation and<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-742311","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Global Initiative to Sharpen Commercial and R&amp;D Focus - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Global Initiative to Sharpen Commercial and R&amp;D Focus - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Company Redesigns Operating Model; Reduces Cost Base Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015 Plan includes new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions Company reaffirmed 2013 full-year non-GAAP EPS target of $3.45 to $3.55; revised GAAP EPS range to $1.58 to $1.82 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a global initiative to sharpen its commercial and research and development (R&amp;D) focus. The multi-year initiative will enable Merck to better target its resources behind those opportunities that have the potential to deliver the greatest return on investment, including bolstering its pipeline and implementing a more agile operating model, with a significantly reduced, more flexible cost structure. \u201cThese actions will make Merck a more competitive company, better positioned to drive innovation and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:34+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131001005957r1&amp;sid=hq1sf1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\\\/\",\"name\":\"Merck Announces Global Initiative to Sharpen Commercial and R&D Focus - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131001005957r1&amp;sid=hq1sf1&amp;distro=nx\",\"datePublished\":\"2013-10-01T06:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131001005957r1&amp;sid=hq1sf1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131001005957r1&amp;sid=hq1sf1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Global Initiative to Sharpen Commercial and R&#038;D Focus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Global Initiative to Sharpen Commercial and R&D Focus - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Global Initiative to Sharpen Commercial and R&D Focus - Merck.com","og_description":"Company Redesigns Operating Model; Reduces Cost Base Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015 Plan includes new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions Company reaffirmed 2013 full-year non-GAAP EPS target of $3.45 to $3.55; revised GAAP EPS range to $1.58 to $1.82 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a global initiative to sharpen its commercial and research and development (R&amp;D) focus. The multi-year initiative will enable Merck to better target its resources behind those opportunities that have the potential to deliver the greatest return on investment, including bolstering its pipeline and implementing a more agile operating model, with a significantly reduced, more flexible cost structure. \u201cThese actions will make Merck a more competitive company, better positioned to drive innovation and","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:34+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131001005957r1&amp;sid=hq1sf1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/","name":"Merck Announces Global Initiative to Sharpen Commercial and R&D Focus - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131001005957r1&amp;sid=hq1sf1&amp;distro=nx","datePublished":"2013-10-01T06:30:00+00:00","dateModified":"2023-03-22T04:04:34+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131001005957r1&amp;sid=hq1sf1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131001005957r1&amp;sid=hq1sf1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-global-initiative-to-sharpen-commercial-and-rd-focus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Global Initiative to Sharpen Commercial and R&#038;D Focus"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"927383e2-c25d-4d26-829e-11d35b1e384b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Global-Initiative-to-Sharpen-Commercial-and-RD-Focus-2013.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742311\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742311"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}